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ABSTRACT
Introduction Behavioural interventions in early life appear
to show some effect in reducing childhood overweight
and obesity. However, uncertainty remains regarding
their overall effectiveness, and whether effectiveness
differs among key subgroups. These evidence gaps have
prompted an increase in very early childhood obesity
prevention trials worldwide. Combining the individual
participant data (IPD) from these trials will enhance
statistical power to determine overall effectiveness and
enable examination of individual and trial-level subgroups.
We present a protocol for a systematic review with IPD
meta-analysis to evaluate the effectiveness of obesity
prevention interventions commencing antenatally or in
the first year after birth, and to explore whether there are
differential effects among key subgroups.
Methods and analysis Systematic searches of Medline,
Embase, Cochrane Central Register of Controlled Trials,
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PsycInfo and trial registries for all ongoing

and completed randomised controlled trials evaluating
behavioural interventions for the prevention of early
childhood obesity have been completed up to March
2021 and will be updated annually to include additional
trials. Eligible trialists will be asked to share their IPD;
if unavailable, aggregate data will be used where
possible. An IPD meta-analysis and a nested prospective
meta-analysis will be performed using methodologies
recommended by the Cochrane Collaboration. The
primary outcome will be body mass index z-score at age
24±6 months using WHO Growth Standards, and effect
differences will be explored among prespecified individual
and trial-level subgroups. Secondary outcomes include
other child weight-related measures, infant feeding,
dietary intake, physical activity, sedentary behaviours,
sleep, parenting measures and adverse events.
Ethics and dissemination Approved by The University
of Sydney Human Research Ethics Committee (2020/273)
and Flinders University Social and Behavioural Research
Ethics Committee (HREC CIA2133-1). Results will be
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Strengths and limitations of this study
► This will be the largest individual participant data (IPD) meta-

►

►
►

►

analysis evaluating behavioural interventions for the prevention of
early childhood obesity to date, and will provide the most reliable
and precise estimates of early intervention effects to inform future
decision-making.
IPD meta-analysis methodology will enable unprecedented exploration of important individual and trial-level characteristics that may
be associated with childhood obesity or that may be effect modifiers.
The proposed innovative methodologies are feasible and have been
successfully piloted by members of our group.
It may not be possible to obtain IPD from all eligible trials; in this instance, aggregate data will be used where available, and sensitivity
analyses will be conducted to assess inclusion bias.
Outcome measures may be collected and reported differently across
included trials, potentially increasing imprecision; however, we will
harmonise available data where possible, and encourage those
planning or conducting ongoing trials to collect common core outcomes following prospective meta-analysis methodology.

relevant to clinicians, child health services, researchers, policy-makers
and families, and will be disseminated via publications, presentations and
media releases.
PROSPERO registration number CRD42020177408.

INTRODUCTION
Childhood obesity is one of the most serious public
health issues of the 21st century, and requires urgent
action.1 2 Globally, an estimated 38 million (6%) children
aged under 5 years were living with overweight or obesity
in 2019,3 and prevalence is increasing across every continent as environments become more obesity conducive.4 5
While childhood obesity affects all sections of society, it
disproportionately affects racial and ethnic minority
groups6 7 and populations with a lower socioeconomic
position (SEP), and thus is also a major health equity
issue.4 Children with obesity are much more likely to have
obesity across the lifecourse,8 9 and are at increased risk
of short-term and long-term negative health sequelae,
such as poor mental and musculoskeletal health, type
2 diabetes, asthma and cardiovascular disease.10 11 This
places a large burden on healthcare systems,12 and
has significant economic consequences arising from
increased disability and decreased productivity and life
expectancy.13 Thus, identifying modifiable behaviours
for the early prevention of childhood obesity is critical to
inform the development of early intervention strategies.
There are a variety of modifiable behaviours that may
influence energy balance and therefore may be implicated in childhood obesity prevention, namely, feeding
practices, dietary intake, physical activity, sedentary
behaviours and sleep. For instance, appropriate responsive feeding has been identified as promising for obesity
prevention,14–16 while consumption of sugar-
sweetened
beverages is associated with severe obesity in children
aged less than 5 years.17 Data are mixed on the protective benefits of breast feeding for the prevention of
2

obesity, though some studies suggest that longer duration
of exclusive breast feeding may provide modest protection.18–23 Similarly, there may be an association between
age at introduction of solids and growth,24 with mixed
results surrounding the direction of this association and
the underlying causal mechanisms. Previous systematic
reviews have reported significant inverse associations
between physical activity and measures of adiposity in
children.25–27 Conversely, sedentary behaviours such
as television viewing or screen time are associated with
higher body mass index (BMI) levels28 29 and greater
adiposity30 in young children. There is now also a large
body of observational evidence supporting the relationship between short sleep duration and an increased risk
of obesity across all age groups, including infants and
young children,31–35 though a recent systematic review
found inconsistent evidence of an association between
longer infant sleep duration and healthier body composition up to age 24 months.36
In addition to these behaviours, individual-level covariates known or hypothesised to be predictive for childhood
obesity include prepregnancy maternal and paternal BMI,
age, race, ethnicity, SEP, excess gestational weight gain,
parity, smoking during pregnancy, gestational diabetes,
birth mode of delivery (caesarean, vaginal), birth weight,
gestational age at birth, baby’s sex, intrapartum antibiotic
prophylaxis and childcare attendance.6 7 22 37 38 Some of
these covariates may also be individual-level effect modifiers, prediciting how effective an intervention is likely to
be, for example, SEP and race/ethnicity. Trial-level characteristics such as timing of intervention onset, setting
and the level of well-
child healthcare available in the
community may also modify intervention effectiveness.39
Limitations and evidence gaps identified in previous reviews
In the past 5 years, there have been numerous reviews of
childhood obesity prevention trials encompassing a variety
of intervention types, settings and age groups.14 40–46 Few
of these focused solely on infancy, and many spanned
multiple life stages from the prenatal period to 18 years
of age. One review found that family-based childhood
obesity prevention interventions most frequently targeted
children 2–10 years of age (78%), with fewer targeting
infants aged 0–1 year (24%) or the prenatal period
(8%).40 Most reviews highlighted the urgent need for
further rigorous evidence to inform obesity prevention
interventions in the very early childhood years.14 40–44 46
Given the consequences of rapid early life weight gain,
associated epigenetic changes and early onset of obesity
in many children,3 47 48 there is strong rationale to start
preventive interventions early when biology is most
amenable to change, and before negative obesity-
conducive behavioural patterns are established.2
Most of the childhood obesity prevention reviews to
date have used qualitative methodology such as narrative
reviews, content analysis and systematic reviews without
meta-
analysis to describe variations in study design,
setting, population, interventions and outcomes, and to
Hunter KE, et al. BMJ Open 2022;12:e048166. doi:10.1136/bmjopen-2020-048166
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hypothesise that certain individual and trial-level characteristics may enhance effectiveness via proposed conceptual frameworks and intervention models.14 40 42–46 Yet,
quantitative evaluation is required to formally test these
hypotheses. Recently, Brown et al41 updated a Cochrane
systematic review and aggregate data meta-
analysis on
obesity prevention in children aged 0–18 years, and
found that interventions focusing on diet and physical
activity combined can lead to a small reduction in BMI
z-score in children aged 0–5 years of age (mean difference −0.07, 95% CI −0.14 to −0.01). However, a huge
variety in intervention approaches limited their ability to
conduct meaningful comparisons, and many multicomponent interventions were originally reported as a whole
package, precluding evaluation of discrete intervention
characteristics. Moreover, the aggregated data were insufficient to derive conclusions on effect differences by
individual-level characteristics such as ethnicity and SEP.
The Early Prevention of Obesity in Children (EPOCH)
Collaboration conducted a world-first individual participant data (IPD) prospective meta-analysis (PMA) of four
randomised controlled trials (RCTs) of behavioural interventions for the prevention of early childhood obesity.39
They found that, compared with usual care, early childhood interventions were modestly effective in reducing
BMI z-score 18–24 months after birth by 0.12 SD (which
translates to a 2% decrease in obesity prevalence).
However, when accounting for missing data this difference was no longer significant. There was some heterogeneity across trials, and interventions appeared to be more
effective in populations with limited publicly funded
existing healthcare programmes, in this instance defined
as a maximum of one postnatal home visit.39 However,
this finding needs to be confirmed in analyses including
more than four studies. EPOCH’s predictive analyses of
individual and trial-level factors did not have sufficient
power to detect reliable differences in BMI z-score. Thus,
the overall effectiveness of early obesity prevention interventions remains uncertain, as does whether there may
be differential effects among subgroups.

sample size for Transforming Obesity Prevention for
CHILDren (TOPCHILD) will exceed these estimates (as
by July 2021, 45 trials including 40 030 eligible participants have already agreed to share their IPD).
Conducting a trial of this size would be time and
resource intensive. A more efficient method is to combine
IPD from trials in a pooled analysis to increase the sample
size and therefore statistical power. This strengthens
the chance of detecting intervention effect differences,
and enables us to determine the size of such effects with
greater certainty,50 while also allowing variation in study
designs and population which heightens generalisability
and allows a greater diversity to study effect modification
for different subgroups of individuals or trial characteristics.51 Moreover, this collaborative approach maximises
the use of existing data, thereby reducing research waste.
Thus, we will conduct an IPD meta-analysis with detailed
subgroup analyses of all available trials to confirm whether
early obesity prevention interventions commencing antenatally or in the first year after birth are effective, and
whether effectiveness varies across subgroups defined by
individual-level or trial-level characteristics. The knowledge generated from this study can be used to inform
decision-making around the design and implementation
of more effective, efficient, equitable and targeted interventions for the prevention of childhood obesity and its
sequelae.
Objectives
This IPD meta-analysis will address the following research
questions:
1. Compared with usual care, no intervention or attentional control, what are the effects of parent/caregiver-
focused behavioural obesity prevention interventions
commencing during pregnancy or infancy on:
a. child BMI z-score at age 24 months (±6 months)?
(primary outcome),
b. child BMI z-score at alternative timepoints, other
child weight-related measures, infant feeding, dietary intake, physical activity, sedentary behaviours,
sleep, parenting measures and adverse events? (secondary outcomes),
level
2. Do intervention effects vary across individual-
characteristics (eg, parental BMI, parity, SEP, birth
weight)?
3. Do intervention effects vary across trial-level characteristics (eg, access to existing well-child healthcare
programmes, intervention mode of delivery, timing of
intervention onset)?

Need for IPD meta-analysis
The limitations and evidence gaps described above highlight the need for more powerful and in-depth analyses
focusing on preventive interventions in very early childhood. Since the EPOCH PMA,39 we have identified more
than 60 additional ongoing or completed very early
obesity prevention trials worldwide with a combined
sample size of more than 50 000 participants. While most
trials are powered to detect some important differences
in key outcomes, individually they have limited power
to detect a difference in our primary outcome, BMI
z-score at 24±6 months of age. In order to reliably detect
a reduction in BMI z-score similar to that seen in EPOCH
(−0.12),39 2920 participants are required (90% power,
2-sided 5% level of significance). Moreover, usually about
four times that sample size (n~12 000) is required to
detect differences in subgroups.49 The expected total

METHODS AND ANALYSIS
We will conduct a systematic review with IPD meta-analysis
and a nested PMA according to the methods recommended by the Cochrane Collaboration.52 53 A nested
PMA enables integration of prospective evidence into a
retrospective meta-
analysis, and harmonisation among
planned/ongoing studies.53 Lead investigators of eligible
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trials will be invited to share their IPD and join the
TOPCHILD Collaboration (www.topchildcollaboration.
org). This protocol adheres to the Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols54
(online supplemental appendix 1).
Eligibility criteria
Types of studies
This systematic review will include RCTs only, including
feasibility studies, pilot trials and definitive trials. Randomisation may occur at the individual level or by cluster
wedge
(eg, child care, community), including stepped-
designs. Quasi-
randomised trials are excluded as they
may introduce bias. There are no language or date
restrictions.
Trial participants
Participants will be parents/caregivers (including pregnant women) and their infant(s) aged 0–12 months (at
baseline). Caregiver is defined as the person with primary
responsibility for care of the child, and excludes secondary
sources of support, such as child care providers and early
childhood teachers. Women may be primipara or multipara, and both singletons and multiples are eligible.
Types of interventions
Interventions must be behavioural interventions targeting
parents/caregivers, and include at least one component
related to modifiable child behaviours that may influence
overweight/obesity risk (eg, infant feeding, dietary intake,
physical activity, sedentary behaviours, sleep). They may
commence in the preconception or antenatal phase but
must include intervention exposure targeting the birth to
12 months infancy stage, as pregnancy-only interventions
are considered distinct and are currently being examined
by Dodd et al in a separate IPD meta-analysis.55 Only childhood obesity prevention-focused trials will be included;
these are defined as trials that clearly state childhood
obesity prevention as a key aim/objective. Interventions
focused only on improving an obesity-related behaviour
(eg, sleep, delayed introduction of solid foods), as well
as those focused on treatment of obesity, stunting or
underweight will be excluded. Trials with a dual focus to
prevent obesity and undernutrition are eligible, though
we will carefully consider and prespecify how their data
will be incorporated in the statistical analysis plan. Interventions focused solely on nutritional supplements will be
excluded, as they are not considered to be behavioural
interventions.
Types of comparator/control
Eligible trials must have either (1) a usual care control
arm, defined as existing local child healthcare, or (2) no
intervention (including waitlist control) or (3) attention
control (eg, child safety education).

score, prevalence of
(at any age), that is, BMI/BMI z-
overweight/obesity, per cent fat content/adiposity, skinfold thickness, abdominal circumference, waist-to-height
ratio. This is considered a legitimate and pragmatic
approach given our review is of multicomponent public
health interventions focusing on obesity.56
Eligibility for nested PMA
In accordance with PMA methodology,53 only planned/
ongoing trials will be eligible for the nested PMA if trial
results were not yet known to the investigator/s at the
time the main components of the TOPCHILD protocol
(ie, aims and objectives, hypotheses, eligibility criteria,
main outcomes, subgroup and sensitivity analyses)
were initially agreed in December 2020. We encourage
investigators of planned/ongoing studies to collect the
outcomes and subgroup variables listed in table 1 where
possible, to facilitate data harmonisation and synthesis.
Information sources and search strategy
In March 2020, we undertook an initial systematic search
for eligible trials using the following databases from their
inception: Medline (Ovid), Embase (Ovid), Cochrane
Central Register of Controlled Trials, CINAHL (EBSCO),
PsycInfo, C
 linicalTrials.gov and the WHO’s International
Clinical Trials Registry Platform’s Search Portal. The
full search strategy is available in online supplemental
appendix 2. This search will be updated annually for the
duration of the TOPCHILD Collaboration (currently
funded until end 2023). Collaborators and contacts will
also be asked to notify us of any planned, ongoing or
completed trials of which they are aware that may meet
the eligibility criteria.
Selection of studies for inclusion in the review
Two members of the TOPCHILD Steering Group will
independently screen all retrieved records against eligibility criteria. Any discrepancies will be resolved by discussion or, if required, adjudication by a third reviewer from
the Steering Group. The Principal Investigator and/or
corresponding author of eligible trials will be invited by
email to join the TOPCHILD Collaboration. If there is no
response to initial emails and reminders, we will contact
co-authors and/or other contacts listed in registration
records and consult our existing networks to see if they
can reach out to those they may know. If IPD cannot be
obtained for an eligible trial, we will use aggregate data
sourced from publications where available.
Online supplemental appendix 3 lists eligible trials
identified up to March 2021.

Types of outcome measures
To be included, trials must collect at least one of the child
weight-related outcomes listed in table 1 post intervention

Data collection, management and confidentiality
Data receipt/extraction
Trialists of all eligible studies will be invited to share
deidentified IPD via secure data transfer platforms or via
secure email using password-
protected
an institutional-
zip files. Data will be provided according to a prespecified coding template where possible. Otherwise, data will
be accepted in any format and recoded as necessary. The
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Table 1 Outcomes and subgroups
Variable

Definition/explanatory text/examples*

Primary outcome
 BMI z-score at age 24 months (±6
months)

 
Determined in accordance with WHO growth standards60

Secondary outcomes

 

 BMI z-score at 12 months (±3 months)

Determined in accordance with WHO growth standards60

 BMI z-score at 48 months (±12 months) Determined in accordance with WHO growth standards60
 BMI z-score beyond 60 months

Determined in accordance with WHO growth standards60

 Other weight-related measures

For example, prevalence of overweight/obesity (defined as BMI z-score of at least
2 SD above the WHO reference), per cent fat content/ adiposity, skinfold thickness,
abdominal circumference, waist-to-height ratio, velocity of weight gain, weight-for-
length, per cent excess BMI >95th percentile, adiposity rebound

 Infant feeding

For example, breast feeding initiation and duration, exclusivity of breast feeding,
age at introduction of solid foods (complementary feeding)

 Dietary intake

For example, energy intake, intake of fruit, vegetables, energy dense nutrient poor
foods, and sugar-sweetened beverages

 Sedentary behaviours

For example, screen time, restrained time while awake (in prams/strollers, high-
chairs, strapped on a caregiver’s back or chest)

 Physical activity

For example, active play duration, prone play (‘tummy time’), device assessed
physical activity time

 Sleep

For example, sleep duration, measures of sleep quality such as frequency and
duration of waking at night

 Parental/caregiver measures

General and domain-specific parenting styles and practices, for example, parenting
self-efficacy, parenting styles, parent feeding practices, parent physical activity
practices, parent sleep practices, stress

 Adverse events

For example, underweight, injuries, infection

Individual-level subgroups
 Socioeconomic position

For example, household income/country median household income, parent/
caregiver highest education level, employment status

 Parental weight status

For example, maternal prepregnancy BMI, paternal BMI

 Race/ethnicity

Trialist defined

 Maternal age

At recruitment

 Maternal gestational weight gain

In kilograms

 Parity

Primipara, multiparous

 Mode of delivery at birth

Caesarean, vaginal

 Birth weight

In grams

 Weight for gestational age

Small for gestational age, appropriate for gestational age, large for gestational age

 Sex

Female, male, uncertain/other

 Gestational age at birth

Preterm, term

 Household composition

For example, 2 versus 1 adult household, siblings, marital status

 Type of pregnancy

Singleton, multiple

 Maternal diabetes

Gestational, type 1, type 2

 Smoking during pregnancy

yes/no

 Infant’s age at enrolment

In months

 Child’s age at final assessment

In months

 Child care attendance

yes/no

Trial-level subgroups
 Delivery mode (intervention)
 Intervention setting

For example, face-to-face, letter, mobile digital device, individual versus group
For example, household residence, community healthcare facility
Continued
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Table 1 Continued
Variable

Definition/explanatory text/examples*

 Intervention dose/intensity

For example, total number of contacts, frequency of contact, duration of contact

 Fidelity

Planned, actual

 Timing of intervention onset

Preconception, antenatal, postnatal

 Timing of intervention completion

Child age in months

 Current level of background care in the Descriptive, categorisation to be determined, for example, expected number
community
of health contacts between birth and 1 year, expectation of attending prenatal
programmes (yes/no), etc.
 Country
 Behavioural±other intervention type

Low, middle, high income
Behavioural intervention(s) alone versus behavioural+other intervention type (eg,
supplement)

*Exact measures and definitions will depend on what the individual trials have collected and the degree to which harmonisation is possible.
Specific details of all outcome measures will be elaborated on in our forthcoming statistical analysis plan, which will be agreed and signed off
by the Collaboration before any data are analysed.
BMI, body mass index.

data management team (within the TOPCHILD Steering
Group) will receive and store the data in perpetuity in
a secure, customised database at the NHMRC Clinical
Trials Centre, University of Sydney, and data management will follow the University of Sydney Data Management
Policy 2014. Each trial will also be asked to provide metadata (ie, data that provides information about their trial
dataset), such as questionnaires, data collection forms
and data dictionaries to aid understanding of the dataset.
Trial-
level data, such as setting, intervention timing,
mode of delivery, comparator/control details, method of
sequence generation, allocation concealment, geographical location, sample size, outcome measures and definitions will be extracted into a database and cross-checked
against any published reports, trial protocols, registration
records and data collection sheets.
Data processing
Data from each trial will be checked with respect to
range, internal consistency, consistency with published
reports and missing items. Integrity of the randomisation
process will be examined by reviewing the chronological
randomisation sequence and pattern of assignment, as
well as the balance of participant characteristics across
intervention and control groups. Any inconsistencies or
missing data will be discussed with trialists and/or data
managers and resolved by consensus. Once finalised,
data from each of the trials will be combined into a single
TOPCHILD Collaboration database.
Risk of bias assessment and certainty of evidence appraisal
Included studies will be assessed for risk of bias by two
independent reviewers from the TOPCHILD Steering
Group using Version 2 of the Cochrane risk-of-bias tool
for randomised trials (RoB 2).57 This tool includes five
domains encompassing bias arising from: the randomisation process, deviations from intended interventions,
missing outcome data, measurement of the outcome and
selection of the reported result. For cluster-randomised
6

trials, bias arising from identification or recruitment
of individual participants within clusters will also be
assessed.45 The certainty of evidence will be assessed
according to Cochrane procedures58 using the Grading
of Recommendations Assessment, Development and
Evaluation approach.59 Any differences will be resolved by
consensus or with a third reviewer from the TOPCHILD
Steering Group.
Primary outcome
The primary outcome will be BMI z-
score at age 24
months (±6 months), determined in accordance with
WHO growth standards.60 We selected BMI z-score, over
other measures such as weight-for-length, in light of accumulating evidence that it is more highly correlated with
weight status in infancy and is better at predicting future
obesity risk.61–65 In addition, WHO BMI for age charts
are applicable to all infants/children regardless of SEP
or ethnicity, which aligns with the global nature of the
TOPCHILD Collaboration.66
Secondary outcomes
All outcomes are detailed in table 1. Where possible, definitions will be standardised, otherwise outcomes will be
used as defined within each trial. Secondary outcomes
include BMI z-score at other timepoints, other measures
of child weight, infant feeding (including breast feeding
and introduction of solid foods), dietary intake, sedentary
behaviours, physical activity and sleep, as well as parent/
caregiver-related measures. We will also assess any adverse
events, such as underweight or poor weight gain.
Subgroups
All included subgroups are listed in table 1. Individual-
level and trial-level subgroup analyses will be conducted
for the primary outcome of BMI z-score at age 24 months
(±6 months). Those of primary interest at the individual
level include SEP, race/ethnicity, prepregnancy maternal/
paternal BMI, maternal age, gestational weight gain and
Hunter KE, et al. BMJ Open 2022;12:e048166. doi:10.1136/bmjopen-2020-048166
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parity, and at the trial level include timing of intervention
onset, current level of background care in the community, recruitment country and mode of delivery.
Where possible, outcomes and subgroups will be
collected as continuous variables to maximise power to
detect intervention effects and interactions, and enable
exploration of any non-linear relationships.67 Dichotomous and categorical variables will also be collected to aid
interpretation, and if data are insufficient for the prespecified subgroup analyses, categories will be collapsed prior
to any analyses being conducted.
Data analysis
A detailed statistical analysis plan will be prepared and
agreed on by the TOPCHILD Collaboration members
prior to any analyses being undertaken. Analyses will
to-
treat principle and include all
follow the intention-
randomised infant–parent/caregiver dyads for which
data are available (including any that were excluded from
the original study analysis). For cluster RCTs, correlated
data will be taken into account by fitting the models using
generalised estimating equations to derive appropriate
standard errors. Correlations between multiples also will
be accounted for in the analyses.
The primary analysis for all outcomes will be conducted
using a one-stage approach combining all available IPD
and aggregate data (where IPD are unavailable) to
reduce the risk of availability bias.68 69 The combined
dataset will be analysed including trial as a random effect.
Models will be chosen appropriate to the outcome type.
Generalised linear models with appropriate distributions
and link functions will be used for continuous and binary
outcomes, while Cox proportional hazards regression
will be used to analyse time-to-event outcomes subject to
censoring. For example, linear models will be used for the
primary outcome while relative risk binomial regression
with log link function will be used for prevalence of overweight/obesity, and Cox models will be used for breast
feeding duration. Where possible, continuous outcomes
and subgroup variables will be analysed on their continuous scale to maximise utility of available data.67
Heterogeneity of intervention effects across trials will
be investigated using quantitative measures (I2) supplemented by graphical presentations as recommended in
the Cochrane Handbook.70 Any notable heterogeneity
identified will be explored further to ascertain if the
combination of trials is appropriate.
Results will be reported using appropriate estimates
of intervention effect (relative risks, mean differences
or hazard ratios) with 95% CIs and associated two-sided
p values. For trials with multiple intervention arms, we
will present the data for each intervention arm compared
with the control arm, with the number of participants in
the control arm adjusted to ensure no double counting.41
Missing data will be explored in sensitivity analyses using
appropriate methods. All analyses will be performed
using the open-source software R.71
Hunter KE, et al. BMJ Open 2022;12:e048166. doi:10.1136/bmjopen-2020-048166

Differences in intervention effect between the prespecified subgroups will be examined by testing a treatment
by subgroup interaction term within the 1-stage-model.
Findings of subgroup analyses will be reported as
exploratory,72 and summarised using a 1-stage-approach
supplemented by graphical presentation in a forest plot
using a 2-
stage-
approach. Non-
linear relationships will
be explored for continuous subgroup variables using a
multivariate meta-analysis of the trend.67
Other exploratory analyses for the primary outcome
will include graphical presentation of BMI z-score distributions to investigate any differences beyond mean differences and examine any non-
linear relationships. The
potential for mediation and moderator analyses using
parent/caregiver measures will be explored and detailed
in a statistical analysis plan after we have extracted information about relevant variables collected by included
trials.
Assessment of selection or publication bias
Potential selection bias and publication bias will be investigated by conducting a nested PMA and comparing
prospectively versus retrospectively included trials in a
sensitivity analysis.53 We will also seek to include any unreported outcomes sourced from each trial’s IPD, which
may alleviate selective outcome reporting bias.52 Lastly,
contour-enhanced funnel plots will be used to examine
whether there are differences in results between more
and less precise studies.
Adjustments for multiple testing
Only one primary outcome was selected for this study
(table 1). For secondary outcomes and subgroup analyses, no formal adjustments will be made for the potential inflation of type 1 error rates due to multiple testing.
Instead, we will follow Schulz and Grimes’ approach54
and recommendations of the Cochrane Collaboration.70
This involves cautious interpretation of the magnitudes
of effect, patterns and consistency of results across related
outcomes and clinical/biological plausibility rather than
focusing on any single statistically significant result in
isolation which can be extremely misleading.70 72
Planned sensitivity analyses
Where possible, the following sensitivity analyses will be
conducted for the primary outcome:
► Two stage approach.
► Including IPD only, that is, excluding trials without
IPD available.55
► Including prospectively included trials only (nested
PMA), that is, planned/ongoing trials for which results
were not yet known to investigator/s at the time the
main components of the TOPCHILD protocol were
agreed.53
► Adjusting for birth weight as a covariate.
► Excluding trials with a high risk of bias for sequence
generation and/or allocation concealment and/or
loss to follow-up.
7
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DISCUSSION
This will be the largest IPD meta-analysis to date of trials
evaluating behavioural obesity prevention interventions
commencing in very early childhood. The findings will
inform next generation obesity prevention initiatives that
are effective, efficient and equitable. Such interventions
could set children on a better health trajectory early on

and reduce the potentially life-long burden of disease
associated with obesity.
The main strengths of this study arise from use of IPD
meta-analysis methodology, which is considered the ‘gold
standard’.73 It involves collecting the raw line-
by-
line
data for each participant in each study from the original trialists. This can improve the quality of data, and
enables more in-depth and precise analyses than would
be possible using only published aggregate data.52 In
particular, IPD meta-analysis will enable thorough exploration of individual-level and trial-level subgroups, so that
we may quantify any differential effects and uncover the
key determinants of successful outcomes. This addresses
the limitations identified in previous reviews of childhood
obesity prevention,39 41 46 where such detailed and sufficiently powered analyses were simply not possible.
A potential limitation of this study is the risk of not
obtaining IPD from all eligible studies, resulting in inclusion bias. Where available, we will include aggregate data
from these studies, and conduct sensitivity analyses with
inclusion of IPD only to explore potential bias.74 Further,
there may be variations across studies in how measures
are collected and reported, which may lead to some
imprecision and difficulties pooling the data. We will seek
to address this using nested PMA methodology, whereby
researchers of planned or ongoing trials are encouraged
to harmonise their trial design and collect core outcome
measures to facilitate meta-analysis and interpretation.53
For completed studies, we will derive common outcome
variables by cleaning, recoding and converting existing
measures where possible.
We plan to complete the first round of study identification and IPD collection by early 2021, then conduct the
primary analyses and disseminate the results by the end
of 2022. Trials that are not completed in time to provide
data for this cycle will remain a part of the TOPCHILD
Collaboration, and their data will be included in future
updates of TOPCHILD. Depending on data availability,
we may consider collecting additional emerging variables
of interest, such as intrapartum antibiotic prophylaxis
and the microbiome, for future TOPCHILD cycles.
This IPD meta-analysis will be conducted in parallel
with a complementary TOPCHILD project (Johnson et
al75 unpublished), which aims to deconstruct childhood
obesity interventions into their components (ie, delivery
features, target behaviours and behaviour change techniques) using systematic, internationally recognised
frameworks and both published and unpublished trial
materials. In future, the resulting dataset curated from
these two projects will be used for predictive modelling
of intervention component effectiveness at an individual
participant level, facilitating a personalised or precision
medicine approach to public health prevention.
The TOPCHILD Collaboration will maximise use of
existing trial data that will enable us to understand and
use the most effective intervention components for
specific population groups and contexts. It will provide
urgently needed evidence to inform development and
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►
►

Excluding trials with a significant conflict of interest
(eg, funded by industry).
The impact of missing data on conclusions about the
intervention effect (if appropriate).

Project management
Membership of the TOPCHILD Collaboration includes
trial representatives from each of the trials contributing
IPD to the project, a Steering Group and an Advisory
Group. Trial representatives have the opportunity to
contribute their expert knowledge to the TOPCHILD
Collaboration and provide input into the protocols,
statistical analysis plan and final results manuscript. The
Steering Group will be responsible for data collection,
management and analysis, as well as communication
within the Collaboration, including newsletter updates,
maintenance of the TOPCHILD website and organisation
of virtual or face-to-face collaborator meetings. The Advisory Group will comprise invited experts in childhood
obesity prevention, IPD meta-analysis, statistics, behaviour
change theory/methods and policy implementation.

ETHICS AND DISSEMINATION
Ethical considerations
IPD will be provided by each included trial on the stipulation that ethical approval has been provided by their
respective Human Research Ethics Committees (or
equivalent), and participants gave informed consent
before enrolment to participate in the initial individual
trials. Trialists remain the custodians of their own data,
which will be deidentified before being shared with the
TOPCHILD Collaboration. Ethical approval for this
project has been granted by The University of Sydney
Human Research Ethics Committee (2020/273) and
Flinders University Social and Behavioural Research
Ethics Committee (project no. HREC CIA2133-1).
Publication policy
TOPCHILD manuscripts will be prepared by the Steering
Group in consultation with the Advisory Group, and circulated to the full Collaboration for comment, revision and
approval prior to submission for publication. Any reports
of the results of this study will be published either in the
name of the collaborative group, or by representatives
of the collaborative group on behalf of the TOPCHILD
Collaboration, as agreed by members of the collaborative
group.
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implementation of effective, efficient and equitable interventions for the prevention of early childhood obesity.
The results will be of prime importance for guideline
developers, policy-makers, consumers and the research
community. Further information and updates on the
TOPCHILD Collaboration can be found at www.topchild
collaboration.org
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Supplementary file 1: PRISMA-P checklist

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015
checklist: recommended items to address in a systematic review protocol*
Section and
topic

Item
No

Checklist item

Page No

ADMINISTRATIVE INFORMATION
Title:
1a Identify the report as a protocol of a systematic review
Identification
Update
1b If the protocol is for an update of a previous systematic review, identify as such
Registration
2 If registered, provide the name of the registry (such as PROSPERO) and registration
number
Authors:
Contact
3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide
physical mailing address of corresponding author
3b Describe contributions of protocol authors and identify the guarantor of the review
Contributions
Amendments
4 If the protocol represents an amendment of a previously completed or published
protocol, identify as such and list changes; otherwise, state plan for documenting
important protocol amendments
Support:
Sources
5a Indicate sources of financial or other support for the review
Sponsor
5b Provide name for the review funder and/or sponsor
Role of
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the
sponsor or
protocol
funder

1,3
n/a
4

1-2
19
n/a

20
20
20

INTRODUCTION
Rationale
Objectives

6 Describe the rationale for the review in the context of what is already known
5-8
7 Provide an explicit statement of the question(s) the review will address with reference to 8
participants, interventions, comparators, and outcomes (PICO)

METHODS
Eligibility criteria

Information
sources
Search strategy

8 Specify the study characteristics (such as PICO, study design, setting, time frame) and
report characteristics (such as years considered, language, publication status) to be used
as criteria for eligibility for the review
9 Describe all intended information sources (such as electronic databases, contact with
study authors, trial registers or other grey literature sources) with planned dates of
coverage
10 Present draft of search strategy to be used for at least one electronic database, including
planned limits, such that it could be repeated

Study records:
Data
11a Describe the mechanism(s) that will be used to manage records and data throughout the
management
review
Selection
11b State the process that will be used for selecting studies (such as two independent
reviewers) through each phase of the review (that is, screening, eligibility and inclusion in
process
meta-analysis)
Data
11c Describe planned method of extracting data from reports (such as piloting forms, done
collection
independently, in duplicate), any processes for obtaining and confirming data from
process
investigators
Data items
12 List and define all variables for which data will be sought (such as PICO items, funding
sources), any pre-planned data assumptions and simplifications
Outcomes and
13 List and define all outcomes for which data will be sought, including prioritization of main
prioritization
and additional outcomes, with rationale

8-10

10

Supplementary
file 2
11
10

11

12-14
12-14
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14 Describe anticipated methods for assessing risk of bias of individual studies, including
whether this will be done at the outcome or study level, or both; state how this
information will be used in data synthesis
15a Describe criteria under which study data will be quantitatively synthesised
15b If data are appropriate for quantitative synthesis, describe planned summary measures,
methods of handling data and methods of combining data from studies, including any
planned exploration of consistency (such as I2, Kendall’s τ)
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses,
meta-regression)
15d If quantitative synthesis is not appropriate, describe the type of summary planned
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies,
selective reporting within studies)
17 Describe how the strength of the body of evidence will be assessed (such as GRADE)

BMJ Open

11

14
14-15
12, 16
n/a
15

Confidence in
11-12
cumulative
evidence
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration
(cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and
dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a
Creative Commons Attribution Licence 4.0.
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred
reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan
2;349(jan02 1):g764
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Supplementary file 2: TOPCHILD search strategy
Ovid MEDLINE
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.

35.

36.
37.
38.
39.
40.
41.
42.

obesity/
pediatric obesity/
overweight/
Weight Gain/
body-weight trajectory/
Body mass index/
Adiposity/
Body weight/
Body Weight Changes/
Skinfold thickness/
Waist-hip-ratio/
Waist circumference/
obes*.tw
(overweight or over weight or over-weight).tw
(weight gain).tw
(BMI or body mass index).tw
adiposity.tw
(body weight).tw
(weight change$).tw
(skin fold thickness).tw
(waist-hip ratio).tw
(waist circumference).tw
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22
child health services/
early intervention, educational/
maternal-child health services/
Maternal-Child Health Centers/
maternal health services/
Mother-Child Relations/
preventive health services/
health education/
health promotion/
((behaviour or behavior) and change).ti,ab
((behavio?r*) adj (therapy or modif* or strateg* or intervention* or advice or program* or class*
or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or workshop* or
module* or consultation* or session*)).ti,ab
((lifestyle or life style) adj (chang* or modif* or strateg* or intervention* or advice or program*
or class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab
(peer adj2 support).ti,ab
education* adj1 (intervention* or program* or class* or counsel* or teach* or workshop* or
module* or consultation* or session*).ti,ab
24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37
Breastfeeding/
Infant Nutritional Physiological Phenomena/
Infant Food/
Diet, Healthy/
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43. ((diet* or nutrition or feeding) adj (modif* or strateg* or intervention* or advice or program* or
class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab
44. ((child or toddler or infant$) adj1 (food or feeding or nutrition$)).ti,ab
45. ((responsive or complementary) adj1 feeding).ti,ab
46. (healthy eating).ti,ab
47. Feeding behavior/
48. 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47
49. Motor activity/
50. Exercise/
51. Sedentary Behavior/
52. (physical activity or physical inactivity).ti,ab
53. sedentary behavio?r.ti,ab
54. (screen time).ti,ab
55. play.ab,ti
56. "tummy time".ab,ti
57. 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56
58. Sleep/
59. Sleep.ti,ab
60. 58 OR 59
61. 38 OR 48 OR 57 OR 60
62. 23 AND 56
63. exp child/
64. exp infant/
65. (babies or baby or boy? or child* or girl? or infan* or kid? or neonat* or neo-nat* or newborn*
or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or toddler?).ti,ab,kf.
66. (pregnan* or perinatal* OR prenatal* OR antenatal OR postnatal*).ti,ab,kf
67. Parents/
68. (parent$ or care giver or caregiver or guardian or family or families or mother$ or father$ OR
maternal OR paternal).tw
69. 63 or 64 or 65 or 66 or 67 or 68
70. 62 AND 69
71. (exp animals/ not humans.sh.) or (rat or rats or mouse or mice or rodent*).ti.
72. 70 not 71
73. randomized controlled trial.pt.
74. controlled clinical trial.pt.
75. randomi#ed.ab.
76. clinical trials as topic.sh.
77. randomly.ab.
78. trial.ti.
79. 73 or 74 or 75 or 76 or 77 or 78
80. 72 AND 79
Embase Classic+Embase
1.
2.
3.
4.
5.
6.

obesity/
pediatric obesity/
overweight/
Weight Gain/
body-weight trajectory/
Body mass index/
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7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.

35.

36.
37.
38.
39.
40.
41.
42.
43.

44.
45.
46.
47.
48.
49.
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Adiposity/
Body weight/
Body Weight Changes/
Skinfold thickness/
Waist-hip-ratio/
Waist circumference/
obes*.tw.
(overweight or over weight or over-weight).tw.
weight gain.tw.
(BMI or body mass index).tw.
adiposity.tw.
body weight.tw.
weight change$.tw.
skin fold thickness.tw.
waist-hip ratio.tw.
waist circumference.tw.
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22
child health services/
early intervention, educational/
maternal-child health services/
Maternal-Child Health Centers/
maternal health services/
Mother-Child Relations/
preventive health services/
health education/
health promotion/
((behaviour or behavior) and change).ti,ab.
(behavio?r* adj (therapy or modif* or strateg* or intervention* or advice or program* or class*
or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or workshop* or
module* or consultation* or session*)).ti,ab.
((lifestyle or life style) adj (chang* or modif* or strateg* or intervention* or advice or program*
or class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
(peer adj2 support).ti,ab.
(education* adj1 (intervention* or program* or class* or counsel* or teach* or workshop* or
module* or consultation* or session*)).ti,ab. (high fat* or low fat* or fatty food*).ti,ab
24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
Breastfeeding/
Infant Nutritional Physiological Phenomena/
Infant Food/
Diet, Healthy/
((diet* or nutrition or feeding) adj (modif* or strateg* or intervention* or advice or program* or
class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
((child or toddler or infant$) adj1 (food or feeding or nutrition$)).ti,ab.
((responsive or complementary) adj1 feeding).ti,ab.
healthy eating.ti,ab.
Feeding behavior/
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
Motor activity/
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50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Exercise/
Sedentary Behavior/
(physical activity or physical inactivity).ti,ab.
sedentary behavio?r.ti,ab.
screen time.ti,ab.
play.ab,ti.
"tummy time".ab,ti.
49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
Sleep/
Sleep.ti,ab.
58 or 59
38 or 48 or 57 or 60
23 and 61
exp child/
exp infant/
(babies or baby or boy? or child* or girl? or infan* or kid? or neonat* or neo-nat* or newborn*
or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or toddler?).ti,ab
(pregnan* or perinatal* or prenatal* or antenatal or postnatal*).ti,ab
Parents/
(parent$ or care giver or caregiver or guardian or family or families or mother$ or father$ or
maternal or paternal).tw.
63 or 64 or 65 or 66 or 67 or 68
62 and 69
(exp animals/ not humans.sh.) or (rat or rats or mouse or mice or rodent*).ti.
70 not 71
exp clinical trial/
exp Randomized Controlled Trial/
randomization/
clinical trial.tw.
random$.tw.
Comparative Study/
(comparison group$ or control group$).tw.
73 or 74 or 75 or 76 or 77 or 78 OR 79
72 and 80

EBM Reviews - Cochrane Central Register of Controlled Trials
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

obesity/
pediatric obesity/
overweight/
Weight Gain/
body-weight trajectory/
Body mass index/
Adiposity/
Body weight/
Body Weight Changes/
Skinfold thickness/
Waist-hip-ratio/
Waist circumference/
obes*.tw.
(overweight or over weight or over-weight).tw.
weight gain.tw.
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16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.

35.

36.
37.
38.
39.
40.
41.
42.
43.

44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
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(BMI or body mass index).tw.
adiposity.tw.
body weight.tw.
weight change$.tw.
skin fold thickness.tw.
waist-hip ratio.tw.
waist circumference.tw.
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22
child health services/
early intervention, educational/
maternal-child health services/
Maternal-Child Health Centers/
maternal health services/
Mother-Child Relations/
preventive health services/
health education/
health promotion/
((behaviour or behavior) and change).ti,ab.
(behavio?r* adj (therapy or modif* or strateg* or intervention* or advice or program* or class*
or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or workshop* or
module* or consultation* or session*)).ti,ab.
((lifestyle or life style) adj (chang* or modif* or strateg* or intervention* or advice or program*
or class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
(peer adj2 support).ti,ab.
(education* adj1 (intervention* or program* or class* or counsel* or teach* or workshop* or
module* or consultation* or session*)).ti,ab.
24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
Breastfeeding/
Infant Nutritional Physiological Phenomena/
Infant Food/
Diet, Healthy/
((diet* or nutrition or feeding) adj (modif* or strateg* or intervention* or advice or program* or
class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
((child or toddler or infant$) adj1 (food or feeding or nutrition$)).ti,ab.
((responsive or complementary) adj1 feeding).ti,ab.
healthy eating.ti,ab.
Feeding behavior/
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
Motor activity/
Exercise/
Sedentary Behavior/
(physical activity or physical inactivity).ti,ab.
sedentary behavio?r.ti,ab.
screen time.ti,ab.
play.ab,ti.
"tummy time".ab,ti.
49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
Sleep/
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59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
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Sleep.ti,ab.
58 or 59
38 or 48 or 57 or 60
23 and 61
exp child/
exp infant/
(babies or baby or boy? or child* or girl? or infan* or kid? or neonat* or neo-nat* or newborn*
or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or toddler?).ti,ab.
(pregnan* or perinatal* or prenatal* or antenatal or postnatal*).ti,ab.
Parents/
(parent$ or care giver or caregiver or guardian or family or families or mother$ or father$ or
maternal or paternal).tw.
63 or 64 or 65 or 66 or 67 or 68
62 and 69

CINAHL Complete (EBSCO Host)
S77
S76
S75
S74
S73
S72
S71
S70
S69
S68
S67
S66
S65
S64
S63

S62
S61
S60
S59
S58
S57
S56
S55
S54
S53
S52
S51
S50

S67 AND S75
S67 AND S75
S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74
TX comparison group*
TX random*
(PT "CLINICAL TRIAL")
(MH "Clinical Trials")
(MH "Random Sample+")
(MH "Random Assignment")
(MH "Comparative Studies")
S65 NOT S66
(MH "Animals+")
S56 AND S64
S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63
(TI parent$ or care giver or caregiver or guardian or family or families or mother$ or
father$ OR maternal OR paternal) OR (AB (parent$ or care giver or caregiver or guardian or
family or families or mother$ or father$ OR maternal OR paternal)
(MH "Parents")
(TI pregnan* or perinatal* or prenatal* or antenatal* or postnatal*) OR (AB pregnan* or
perinatal* or prenatal* or antenatal* or postnatal*)
(AB babies or baby or boy? or girl? or child* or infan* or kid? or neonat* or neo-nat* or
newborn* or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or toddler?)
(TI babies or baby or boy? or girl? or child* or infan* or kid? or neonat* or neo-nat* or
newborn* or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or toddler?)
(MH "Infant+")
(MH "Child+")
S17 AND S55
S31 OR S44 OR S51 OR S54
S52 OR S53
(TI sleep) OR (AB sleep)
(MH "Sleep")
S45 OR S46 OR S47 OR S48 OR S49 OR S50
(TI "tummy time") OR (AB "tummy time")
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S49
S48
S47
S46
S45
S44
S43
S42
S41
S40
S39

S38

S37

S36

S35
S34
S33
S32
S31
S30
S29
S28
S27

S26
S25

BMJ Open

(TI play) OR (AB play)
(TI screen time) OR (AB screen time)
(TI sedentary behavio?r) or (AB sedentary behavio?r)
(TI physical activity or physical inactivity) OR (AB physical activity or physical inactivity)
(MH "Exercise")
S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43
(MH "Eating Behavior")
(TI healthy eating) OR (AB healthy eating)
(TI "responsive feed*") OR (AB "responsive feed*")
(TI "complementary feeding") OR (AB "complementary feeding")
(AB nutrition N2 modif*) or (AB nutrition N2 strateg*) or (AB nutrition N2 intervention*) or
(AB nutrition N2 advice) or (AB nutrition N2 program*) or (AB nutrition N2 class*) or (AB
nutrition N2 counsel*) or (AB nutrition N2 educat*) or (AB nutrition N2 instruct*) or (AB
nutrition N2 teach*) or (AB nutrition N2 train*) or (AB nutrition N2 guidance) or (AB
nutrition N2 lesson*) or (AB nutrition N2 workshop*) or (AB nutrition N2 module*) or (AB
nutrition N2 consultation*) or (AB nutrition N2 sess ...
(AB diet* N2 modif*) or (AB diet* N2 strateg*) or (AB diet* N2 intervention*) or (AB diet*
N2 advice) or (AB diet* N2 program*) or (AB diet* N2 class*) or (AB diet* N2 counsel*) or
(AB diet* N2 educat*) or (AB diet* N2 instruct*) or (AB diet* N2 teach*) or (AB diet* N2
train*) or (AB diet* N2 guidance) or (AB diet* N2 lesson*) or (AB diet* N2 workshop*) or (AB
diet* N2 module*) or (AB diet* N2 consultation*) or (AB diet* N2 session*)
(TI nutrition N2 modif*) or (TI nutrition N2 strateg*) or (TI nutrition N2 intervention*) or (TI
nutrition N2 advice) or (TI nutrition N2 program*) or (TI nutrition N2 class*) or (TI nutrition
N2 counsel*) or (TI nutrition N2 educat*) or (TI nutrition N2 instruct*) or (TI nutrition N2
teach*) or (TI nutrition N2 train*) or (TI nutrition N2 guidance) or (TI nutrition N2 lesson*) or
(TI nutrition N2 workshop*) or (TI nutrition N2 module*) or (TI nutrition N2 consultation*) or
(TI nutrition N2 sess ...
(TI diet* N2 modif*) or (TI diet* N2 strateg*) or (TI diet* N2 intervention*) or (TI diet* N2
advice) or (TI diet* N2 program*) or (TI diet* N2 class*) or (TI diet* N2 counsel*) or (TI diet*
N2 educat*) or (TI diet* N2 instruct*) or (TI diet* N2 teach*) or (TI diet* N2 train*) or (TI
diet* N2 guidance) or (TI diet* N2 lesson*) or (TI diet* N2 workshop*) or (TI diet* N2
module*) or (TI diet* N2 consultation*) or (TI diet* N2 session*)
(MH "Infant Feeding")
(MH "Infant Food")
(MH "Infant Nutritional Physiology")
(MH "Breast Feeding")
S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30
(TI counselling or counseling) OR (AB counselling or counseling)
(TI peer N2 support) OR (AB peer N2 support)
(TI home visit) OR (AB home visit)
(TI education N2 intervention*) OR (TI education N2 program*) OR (TI education N2 class*)
OR (TI education N2 counsel*) OR (TI education N2 teach*) OR (TI education N2 workshop)
OR (TI education N2 module*) OR (TI education N2 consultation*) OR (TI education N2
session*) (AB education N2 intervention*) OR (AB education N2 program*) OR (AB
education N2 class*) OR (AB education N2 counsel*) OR (AB education N2 teach*) OR (AB
education N2 workshop) OR (AB education N2 module*) OR (AB education N2 c ...
(MM "Behavior Modification")
(MM "Behavioral Changes")
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S24 (TI behaviour change) OR (AB behaviour change) OR (TI behavior change) OR (AB behavior
change)
S23 (MH "Health Promotion")
S22 (MH "Health Education")
S21 (MH "Mother-Child Relations") OR (MH "Mother-Infant Relations")
S20 (MH "Maternal Health Services") OR (MH "Maternal-Child Health")
S19 (MH "Early Childhood Intervention")
S18 (MH "Child Health Services")
S17 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
OR S15 OR S16
S16 (TI waist-hip ratio or waist circumference) OR (AB waist-hip ratio or waist circumference)
S15 (TI skin fold thickness) OR (AB skin fold thickness)
S14 (TI weight change*) OR (AB weight change*)
S13 (TI body weight) OR (AB body weight)
S12 (TI adiposity) OR (AB adiposity)
S11 (TI BMI or body mass index) OR (AB BMI or body mass index)
S10 (TI weight gain) OR (AB weight gain)
S9 (TI overweight or over weight) OR (AB overweight or over weight)
S8 (TI obese or obesity) OR (AB obese or obesity)
S7 (MH "Waist Circumference")
S6 (MH "Waist-Hip Ratio")
S5 (MH "Skinfold Thickness")
S4 (MH "Body Weight")
S3 (MH "Body Mass Index")
S2 (MH "Weight Gain") OR (MH "Body Weight Changes")
S1 (MH "Obesity") OR (MH "Pediatric Obesity")

APA PsycInfo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

obesity/
overweight/
Weight Gain/
Body mass index/
Body weight/
obes*.tw.
(overweight or over weight or over-weight).tw.
weight gain.tw.
(BMI or body mass index).tw.
adiposity.tw.
body weight.tw.
weight change$.tw.
skin fold thickness.tw.
waist-hip ratio.tw.
waist circumference.tw.
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
Mother-Child Relations/
preventive health services/
health education/
health promotion/
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21 ((behaviour or behavior) and change).ti,ab.
22 (behavio?r* adj (therapy or modif* or strateg* or intervention* or advice or program* or
class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
23 ((lifestyle or life style) adj (chang* or modif* or strateg* or intervention* or advice or
program* or class* or counsel* or educat* or instruct* or teach* or train* or guidance or
lesson* or workshop* or module* or consultation* or session*)).ti,ab.
24 (peer adj2 support).ti,ab.
25 (education* adj1 (intervention* or program* or class* or counsel* or teach* or workshop* or
module* or consultation* or session*)).ti,ab.
26 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 Breast Feeding/
28 ((diet* or nutrition or feeding) adj (modif* or strateg* or intervention* or advice or program*
or class* or counsel* or educat* or instruct* or teach* or train* or guidance or lesson* or
workshop* or module* or consultation* or session*)).ti,ab.
29 ((child or toddler or infant$) adj1 (food or feeding or nutrition$)).ti,ab.
30 ((responsive or complementary) adj1 feeding).ti,ab.
31 healthy eating.ti,ab.
32 Feeding behavior/
33 27 or 28 or 29 or 30 or 31 or 32
34 Exercise/
35 Sedentary Behavior/
36 (physical activity or physical inactivity).ti,ab.
37 sedentary behavio?r.ti,ab.
38 screen time.ti,ab.
39 play.ab,ti.
40 "tummy time".ab,ti.
41 34 or 35 or 36 or 37 or 38 or 39 or 40
42 Sleep/
43 Sleep.ti,ab.
44 42 or 43
45 (babies or baby or boy? or child* or girl? or infan* or kid? or neonat* or neo-nat* or
newborn* or new-born* or paediatric* or peadiatric* or pediatric* or perinat* or
toddler?).ti,ab.
46 (pregnan* or perinatal* or prenatal* or antenatal or postnatal*).ti,ab.
47 Parents/
48 (parent$ or care giver or caregiver or guardian or family or families or mother$ or father$ or
maternal or paternal).tw.
49 45 or 46 or 47 or 48
50 26 or 33 or 41 or 44
51 16 and 50
52 49 and 51
53 (exp animals/ not humans.sh.) or (rat or rats or mouse or mice or rodent*).ti.
54 52 not 53
55 exp experimental design/
56 randomi#ed.ti,ab.
57 randomly.ab.
58 exp clinical trials/
59 trial.ti.
60 exp randomized controlled trial/
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61 55 or 56 or 57 or 58 or 60
62 54 and 61
63 limit 62 to yr="2020 - 2021"
WHO ICTRP
Basic search
1. babies AND obesity
2. babies AND obese
3. babies AND overweight
4. infant AND obesity
5. infant AND obese
6. infant AND overweight
7. infants AND obesity
8. infants AND obese
9. infants AND overweight
10. child AND obesity
11. child AND obese
12. child AND overweight
13. children AND obesity
14. children AND obese
15. children AND overweight
16. childhood AND obesity
17. childhood AND obese
18. childhood AND overweight
19. pediatric AND obesity
20. paediatric AND obesity
21. pediatric AND obese
22. paediatric AND obese
23. pediatric AND overweight
24. paediatric AND overweight
25. toddler AND obesity
26. toddler AND obese
27. toddler AND overweight
28. toddlers AND obesity
29. toddlers AND obese
30. toddlers AND overweight
31. kids AND obesity
32. kids AND obese
33. kids AND overweight

Clinicaltrials.gov
Advanced search
Condition or disease: overweight OR obesity OR obese OR adiposity OR BMI OR
weight gain
Other Terms: baby OR infant OR child OR paediatric OR pediatric OR toddler OR
offspring
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